Prescription Freedom: Maharashtra Cracks Down on Hospital Pharmacy Monopoly

Maharashtra’s Food and Drug Administration (FDA) has issued a landmark directive prohibiting hospitals from forcing patients to purchase medicines exclusively from their in-house pharmacies.

MUMBAI — Patients across Maharashtra are set to gain greater control over their medical expenses as the state’s Food and Drug Administration (FDA) launches a decisive crackdown on hospitals that mandate in-house pharmacy purchases. In a formal order issued on June 12, 2026, FDA Commissioner Tukaram Mundhe declared that compelling patients to buy medicines only from pharmacies located within hospital premises is an unfair trade practice and a violation of consumer rights.

The directive follows numerous complaints from patients and their families alleging that hospitals often withhold prescriptions or route them directly to internal pharmacies, denying families the opportunity to compare prices or utilize neighborhood medical stores.

Ending the Forced-Purchase Culture

Under the new regulations, doctors and hospitals are strictly prohibited from refusing to hand over prescriptions to patients or their relatives. The FDA mandate establishes that:

• Prescription Transparency: Doctors must provide a physical or digital copy of the prescription directly to the patient, ensuring they have the autonomy to source medication from any licensed pharmacy of their choice.

• Prohibition of Coercion: Hospitals are barred from linking admission or treatment to the purchase of medicines from their own pharmacies.

• Mandatory Disclosure: All hospitals in the state are now required to prominently display bilingual notices (in Marathi and English) at their entrances and pharmacies, explicitly stating that patients are free to purchase medicines from any licensed pharmacy outside the hospital.

"Medicines are a fundamental right of the patient, and the choice of where to purchase them is a basic consumer freedom that the administration is committed to protecting," Commissioner Tukaram Mundhe stated, emphasizing that the department would not tolerate practices that prioritize institutional profit over patient welfare.

Regulatory Enforcement and Legal Consequences

The Maharashtra FDA has warned that any hospital, doctor, or pharmacy found violating these directives will face severe legal consequences. Commissioner Mundhe has instructed all divisional joint commissioners, assistant commissioners, and drug inspectors across the state to conduct surprise inspections and ensure immediate compliance.

The move is being viewed as a significant consumer protection measure under the Consumer Protection Act, 2019. By dismantling the "aftermarket" monopoly that hospitals often hold over admitted patients—who are frequently in no position to bargain or travel during medical emergencies—the FDA aims to introduce transparency into the often opaque billing structures of private healthcare.

Practical Implications and Challenges

While the directive has been widely welcomed by patient advocacy groups and health activists, it has also sparked a debate regarding practical implementation. Healthcare professionals point out that in emergency or intensive care situations, the availability of specific, often niche, pharmaceutical brands—which may not be stocked by smaller retail pharmacies—remains a hurdle.

Kailas Tandale, president of the Maharashtra Registered Pharmacists Association, noted that while the freedom of choice is a positive step, it must be paired with broader reforms. "Patients should have the freedom to buy medicines anywhere, but that choice must be practical. The government must ensure that commonly prescribed brands are readily available in the open market," he stated.

Why It Matters

This regulation addresses a long-standing grievance in India’s healthcare system, where "lock-in" effects often leave patients vulnerable to high markups. By codifying the patient's right to choose, Maharashtra is setting a regulatory precedent that could influence healthcare policy across other Indian states, putting public interest and transparency at the forefront of medical governance.

Key Facts at a Glance

• New Directive: Hospitals cannot force patients to buy from in-house pharmacies.

• Mandatory Transparency: Prescriptions must be handed over to patients or relatives.

• Public Notices: Hospitals must display signs in Marathi and English informing patients of their right to choose their pharmacy.

• Enforcement: FDA inspectors are authorized to initiate legal action against non-compliant institutions.

FAQ

Can hospitals refuse to give me my prescription? No. Under the new FDA order, doctors are required to hand over the prescription to you or your relatives, and they cannot withhold it or send it directly to an in-house pharmacy without your consent.

What should I do if a hospital forces me to buy medicine from their shop? Patients are encouraged to register a complaint with their local FDA divisional office or assistant commissioner. The government has urged citizens to report any instances of coercion or refusal to provide prescriptions.

Is this order limited to private hospitals? The order applies broadly to hospitals, medical practitioners, and affiliated pharmacies across Maharashtra to protect consumer rights within the state's healthcare ecosystem.

Official Sources

• Maharashtra Food and Drug Administration (FDA) - Directive Dated June 12, 2026

• NDTV Profit: Exclusive Interview with Tukaram Mundhe

• Business Standard: Coverage of Maha FDA Hospital Pharmacy Order